Cumberland Pharmaceuticals (CPIX) Income from Continuing Operations (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 3140971.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 3140971.0, down 351.64% year-over-year; the trailing twelve-month figure through Mar 2026 was 7240390.0 (down 119.87% YoY), and the FY2025 annual result was 2851235.0, up 55.75% from the prior year.
• Income from Continuing Operations came in at 3140971.0 for Q1 2026 at Cumberland Pharmaceuticals, down from 1415166.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 1248184.0 in Q1 2025 to a low of 6301987.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 1402433.0 (2022), against an average of 1436278.0.
• Across the five-year window, Income from Continuing Operations plunged 1204.25% in 2024 and soared 165.61% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Income from Continuing Operations stood at 2459714.0 in 2022, then plunged by 156.21% to 6301987.0 in 2023, then jumped by 69.82% to 1901637.0 in 2024, then increased by 25.58% to 1415166.0 in 2025, then tumbled by 121.95% to 3140971.0 in 2026.
• The last three Income from Continuing Operations figures came in at 3140971.0 (Q1 2026), 1415166.0 (Q4 2025), and 1949046.0 (Q3 2025), per Business Quant data.